Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain scans reveal diabetes link to cognitive decline in rare disease

NCT ID NCT04656210

Knowledge-focused Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether diabetes or blood sugar problems can worsen thinking and memory issues in people with myotonic dystrophy type 1. Researchers will use MRI brain scans and thinking tests over 4 years to track changes. The goal is to understand why some patients have more severe cognitive problems than others.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

85 people

The number who actually took part.

Started

Oct 2021

Expected to finish

Jan 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with DM type 1 monitored annually by the Neuromuscular Disease Reference Centre

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Molecularly proven type 1 myotonic dystrophy * Voluntary, having given informed consent * Socially insured patient * Patient willing to comply with all study procedures and duration (3 hours + MRI 35 minutes) * Patient insured under the French social security system * Signed consent form Exclusion Criteria: * Neurological history other than neuropathy: epilepsy, stroke, dementia * Pregnancy or breastfeeding or woman of childbearing age without effective contraception (a pregnancy test will be done) * Contra indication to MRI * Person under guardianship or curators * Persons of full age deprived of their liberties by a judicial or administrative decision * Major comorbidity considered as a contraindication by the investigator (cancer, unstable angina, etc.).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Carbohydrate intolerance are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes mellitus glucose-galactose malabsorption metabolic syndrome X myotonic dystrophy myotonic dystrophy type 1 tauopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Carbohydrate intolerance Diabetes Myotonic dystrophy 1

Contacts and locations

Locations

  • Hopital Roger Salengro, CHU Lille

    Lille, 59037, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.